Yong Yang

中国科学家在线 Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 14

Top Venues

Cancer medicine

BMC cancer

Leukemia & lymphoma

Journal of medical Internet research

Chinese Academy of Medical Sciences and Peking Union Medical College (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Chinese Academy of Medical Sciences and Peking Union Medical College Sep 01 2013 - Jul 01 2016

China

PHD

Publications

Wan-Ru Zhang, Xin Liu, Qiu-Zi Zhong, Tao Wu, Yong Yang, Bo Chen, Hao Jing, Yuan Tang, Jing Jin, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Ning-Ning Lu, Ning Li, Yi-Rui Zhai, Wen-Wen Zhang, Shu-Lian Wang, Fan Chen, Lin Yin, Shu-Nan Qi, Ye-Xiong Li
Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. Cancer medicine 13 (1) (2024)
Wan-Ru Zhang, Xin Liu, Qiu-Zi Zhong, Tao Wu, Yong Yang, Bo Chen, Hao Jing, Yuan Tang, Jing Jin, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Ning-Ning Lu, Ning Li, Yi-Rui Zhai, Wen-Wen Zhang, Shu-Lian Wang, Fan Chen, Lin Yin, Shu-Nan Qi, Ye-Xiong Li
Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. Cancer medicine (2024)
Wan-Ru Zhang, Xin Liu, Qiu-Zi Zhong, Tao Wu, Yong Yang, Bo Chen, Hao Jing, Yuan Tang, Jing Jin, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Ning-Ning Lu, Ning Li, Yi-Rui Zhai, Wen-Wen Zhang, Shu-Lian Wang, Fan Chen, Lin Yin, Shu-Nan Qi, Ye-Xiong Li
Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. Cancer medicine (2024)
Wan-Ru Zhang, Xin Liu, Qiu-Zi Zhong, Tao Wu, Yong Yang, Bo Chen, Hao Jing, Yuan Tang, Jing Jin, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Ning-Ning Lu, Ning Li, Yi-Rui Zhai, Wen-Wen Zhang, Shu-Lian Wang, Fan Chen, Lin Yin, Shu-Nan Qi, Ye-Xiong Li
Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. Cancer medicine (2024)
Wan-Ru Zhang, Xin Liu, Qiu-Zi Zhong, Tao Wu, Yong Yang, Bo Chen, Hao Jing, Yuan Tang, Jing Jin, Yue-Ping Liu, Yong-Wen Song, Hui Fang, Ning-Ning Lu, Ning Li, Yi-Rui Zhai, Wen-Wen Zhang, Shu-Lian Wang, Fan Chen, Lin Yin, Shu-Nan Qi, Ye-Xiong Li
Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. Cancer medicine (2024)
Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. BMC cancer 23 (1) (2023)
Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. BMC cancer 23 (1) (2023)
Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. BMC cancer 23 (1) (2023)
Zewei Zhang, Chunxia Xie, Tiantian Gao, Yuxian Yang, Yong Yang, Lei Zhao
Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma-an exploration of surrogate endpoint. BMC cancer 23 (1) (2023)
Yong Yang, Ji-Jin Wang, Rui-Zhi Zhao, Cheng Huang, Gui-Qing Shi, Hao Zheng, Tian-Lan Tang, Si-Qin Liao, Jin-Hua Chen, Jian-Zhen Shen, Ting-Bo Liu, Ben-Hua Xu, Yu-Jing Zhang
The value of routine bone marrow examination in patients with extranodal NK/T-cell lymphoma staged with PET/CT. Cancer 128 (22) (2022)
Yu-Xian Yang, Yu-Zhen Zheng, Tian-Tian Gao, Shi-Liang Liu, Mian Xi, Meng-Zhong Liu, Jun-Ye Wang, Shu-Nan Qi, Yong Yang, Lei Zhao
Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma. Cancer medicine 11 (20) (2022)
Bin Liang, Na Yang, Guosheng He, Peng Huang, Yong Yang
Identification of the Facial Features of Patients With Cancer: A Deep Learning-Based Pilot Study. Journal of medical Internet research 22 (4) (2020)
Shu-Nan Qi, Li-Ming Xu, Zhi-Yong Yuan, Tao Wu, Su-Yu Zhu, Mei Shi, Hang Su, Ying Wang, Xia He, Li-Ling Zhang, Gang Wu, Bao-Lin Qu, Li-Ting Qian, Xiao-Rong Hou, Fu-Quan Zhang, Yu-Jing Zhang, Yuan Zhu, Jian-Zhong Cao, Sheng-Min Lan, Jun-Xin Wu, Yong Yang, Ye-Xiong Li
Effect of primary tumor invasion on treatment and survival in extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: a multicenter study from the China Lymphoma Collaborative Group (CLCG). Leukemia & lymphoma 60 (11) (2019)
Tao Wu, Yong Yang, Su-Yu Zhu, Mei Shi, Hang Su, Ying Wang, Xia He, Li-Ming Xu, Zhi-Yong Yuan, Li-Ling Zhang, Gang Wu, Bao-Lin Qu, Li-Ting Qian, Xiao-Rong Hou, Fu-Quan Zhang, Yu-Jing Zhang, Yuan Zhu, Jian-Zhong Cao, Sheng-Min Lan, Jun-Xin Wu, Chen Hu, Shu-Nan Qi, Bo Chen, Ye-Xiong Li
Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood advances 2 (18) (2019)

Yong Yang.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yong Yang